This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN)

Tipranks - Tipranks - Thu May 14, 10:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN) with bullish sentiments.

Claim 55% Off TipRanks

Savara (SVRA)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Savara today and set a price target of $10.00. The company’s shares closed last Wednesday at $5.06, close to its 52-week high of $5.34.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 23.9% and a 54.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Madrigal Pharmaceuticals. ;'>

Currently, the analyst consensus on Savara is a Strong Buy with an average price target of $11.00, implying a 128.2% upside from current levels. In a report issued on May 5, Piper Sandler also maintained a Buy rating on the stock with a $16.00 price target.

See today’s best-performing stocks on TipRanks >>

Encompass Health (EHC)

Bank of America Securities analyst Joanna Gajuk maintained a Buy rating on Encompass Health today. The company’s shares closed last Wednesday at $107.79.

According to TipRanks.com, Gajuk is a 2-star analyst with an average return of 0.0% and a 48.4% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Brookdale Senior Living. ;'>

Encompass Health has an analyst consensus of Strong Buy, with a price target consensus of $141.25, representing a 31.3% upside. In a report issued on May 1, TipRanks – OpenAI also upgraded the stock to Buy with a $111.00 price target.

SI-Bone (SIBN)

Bank of America Securities analyst Travis Steed maintained a Buy rating on SI-Bone today. The company’s shares closed last Wednesday at $14.52.

According to TipRanks.com, Steed is a 1-star analyst with an average return of -0.4% and a 44.7% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

SI-Bone has an analyst consensus of Strong Buy, with a price target consensus of $22.17, implying a 61.8% upside from current levels. In a report issued on May 11, Canaccord Genuity also maintained a Buy rating on the stock with a $27.00 price target.

Read More on SVRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).